## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasilington,	D.C.	20040

STATEMENT	OF CHANG	ES IN BENEFICIAL	OWNERSHIP

OMB APPROVAL		
OMB Number:	3235-0287	
Estimated average burden		
hours per response:	0.5	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 1. Name and Address of Reporting Person\* Sana Biotechnology, Inc. [ SANA ] **Harr Steve** X Director 10% Owner Officer (give title Other (specify X below) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) below) (Last) (First) 03/03/2022 President & CEO C/O SANA BIOTECHNOLOGY, INC. 188 EAST BLAINE STREET, SUITE 400 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) X Form filed by One Reporting Person **SEATTLE** 98102 WA Form filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 7. Nature of 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership Securities
Beneficially
Owned Following Form: Direct (D) or Indirect (I) (Instr. 4) Indirect Beneficial **Execution Date** Transaction if any (Month/Day/Year) Code (Instr 8) (Month/Day/Year) Ownership Reported (Instr. 4) nsaction(s Code ν Price (Instr. 3 and 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 5. Number of 6. Date Exercisable and 9. Number of 1. Title of 3. Transaction 3A. Deemed . Title and Amount 8. Price of 11. Nature 2. Conversion Ownership Derivative **Execution Date** Transaction Derivative of Securities Derivative derivative of Indirect or Exercise Price of Derivative (Month/Day/Year Underlying Derivative Security (Instr. 3 and 4) Form: Direct (D) or Indirect Security (Instr. 3) if any (Month/Day/Year) Code (Instr. 8) Securities (Month/Day/Year) Security (Instr. 5) Securities Beneficially Beneficial Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Ownership (Instr. 4) Owned Following (I) (Instr. 4) Security Reported Transaction(s) (Instr. 4) Amount Expiration Date Number of Shares Date Exercisable Title Code (A) (D)

(1)

03/02/2032

## **Explanation of Responses:**

\$5.7

1. The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter.

## Remarks:

Stock Options

(Right to Buy)

> /s/ James J. MacDonald, Attorney-in-Fact for Steve Harr

760,000

Stock

\$0.00

03/08/2022

760,000

D

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

03/03/2022

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

760,000